Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05325632 · ClinicalTrials.gov registry record · Phase 2

Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

A Phase 2 study of HER2-positive Breast Cancer, sponsored by H. Lee Moffitt Cancer Center and Research Institute.

Recruiting
Registry status
Phase 2
Development phase
53
Enrollment target
1
Study location

NCT05325632 is a Phase 2 study of HER2-positive Breast Cancer that is actively recruiting participants, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 53 participants, below the 239-participant average among 54 other HER2-positive Breast Cancer trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05325632, a Phase 2 study of HER2-positive Breast Cancer, is actively recruiting participants, sponsored by H. Lee Moffitt Cancer Center and Research Institute.

RECRUITING
Registry status
Phase 2
Development phase
53 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study is to find out if an investigational drug called Dendritic Cell (DC1) vaccine added to standard neoadjuvant (given before main treatment) therapy can help people with HER2 (human epidermal growth factor receptor 2) positive breast cancer.

Conditions Studied

HER2-positive Breast Cancer

Interventions

  • DRUG Trastuzumab
  • DRUG Paclitaxel
  • DRUG Pertuzumab
  • BIOLOGICAL HER-2 pulsed DC1
  • PROCEDURE Resection surgery

Study Locations (1)

Florida

  • Moffitt Cancer Center - Tampa

Trial Details

FieldValue
Enrollment Target 53 participants
Start Date 2021-10-28
Est. Completion 2027-09
Phase Phase 2

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

502 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05325632

The ClinicalTrials.gov registry entry for NCT05325632 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 239-participant average among 54 other HER2-positive Breast Cancer trials with a reported enrollment target (78% lower). The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HER2-positive Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Trastuzumab is the first listed.

NCT05325632 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT05325632 about?

NCT05325632 is a clinical study titled "Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab". The purpose of the study is to find out if an investigational drug called Dendritic Cell (DC1) vaccine added to standard neoadjuvant (given before main treatment) therapy can help people with HER2 (human epidermal growth factor receptor 2) positive breast cancer.

What is the current status of trial NCT05325632?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2021-10-28. Estimated completion is 2027-09.

What conditions does trial NCT05325632 study?

This clinical trial studies the following conditions: HER2-positive Breast Cancer.

What interventions are being tested in trial NCT05325632?

The interventions under investigation include: Trastuzumab (DRUG), Paclitaxel (DRUG), Pertuzumab (DRUG), HER-2 pulsed DC1 (BIOLOGICAL), Resection surgery (PROCEDURE).

Who is sponsoring clinical trial NCT05325632?

This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05325632 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HER2-positive Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HER2-positive Breast Cancer

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.